The role of autologous stem cell transplantation in the treatment of diffuse large b-cell lymphoma

Advances in Hematology

Volumn 2012, Issue , 2012, Pages

  Gunnellini, Marco ^a   Emili, Rita ^a   Coaccioli, Stefano ^a   Liberati, Anna Marina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; EPIRUBICIN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; SALVAGE THERAPY; TREATMENT RESPONSE;

EID: 84856395037     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2012/195484     Document Type: Review

References (58)

1. Tilly H., Dreyling M., Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Annals of Oncology 2010 21 5 v172 v174
2. Boffetta P., Epidemiology of adult non-Hodgkin lymphoma Annals of Oncology 2011 22, supplement 4 iv27 iv31
3. Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Miller T. P., Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma New England Journal of Medicine 1993 328 14 1002 1006 (Pubitemid 23095683)
4. Shipp M. A., Harrington D. P., Andersen J. R., Armitage J. O., Bonadonna G., Brittinger G., Cabanillas F., Canellos G. P., Coiffier B., Connors J. M., Cowan R. A., Crowther D., Dahlberg S., Engelhard M., Fisher R. I., Gisselbrecht C., Horning S. J., Lepage E., Lister T. A., A predictive model for aggressive non-Hodgkin's lymphoma New England Journal of Medicine 1993 329 14 987 994 (Pubitemid 23307906)
5. Traullé C., Coiffier B. B., Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma Future Oncology 2005 1 3 297 306
6. Coiffier B., Lepage E., Brire J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., Gisselbrecht C., Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma New England Journal of Medicine 2002 346 4 235 242 (Pubitemid 34438862)
7. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., Christian B., Lepage E., Tilly H., Morschhauser F., Gaulard P., Salles G., Bosly A., Gisselbrecht C., Reyes F., Coiffier B., Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d'etude des lymphomes de l'adulte Journal of Clinical Oncology 2005 23 18 4117 4126 (Pubitemid 46211317)
8. Pfreundschuh M., Trmper L., sterborg A., Pettengell R., Trneny M., Imrie K., Ma D., Gill D., Walewski J., Zinzani P.-L., Stahel R., Kvaloy S., Shpilberg O., Jaeger U., Hansen M., Lehtinen T., Lpez-Guillermo A., Corrado C., Scheliga A., Milpied N., Mendila M., Rashford M., Kuhnt E., Loeffler M., CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncology 2006 7 5 379 391
9. Sehn L. H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., Klasa R., Savage K. J., Shenkier T., Sutherland J., Gascoyne R. D., Connors J. M., The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 2007 109 5 1857 1861 (Pubitemid 46348180)
10. Ziepert M., Hasenclever D., Kuhnt E., Glass B., Schmitz N., Pfreundschuh M., Loeffler M., Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era Journal of Clinical Oncology 2010 28 14 2373 2380
11. Philip T., Guglielmi C., Hagenbeek A., Somers R., Van der Lelie H., Bron D., Sonneveld P., Gisselbrecht C., Cahn J. Y., Harousseau J. L., Coiffier B., Biron P., Mandelli F., Chauvin F., Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New England Journal of Medicine 1995 333 23 1540 1545
12. Verdonck L. F., Van Putten W. L. J., Hagenbeek A., Schouten H. C., Sonneveld P., Van Imhoff G. W., Kluin-Nelemans H. C., Raemaekers J. M. M., Van Oers R. H. J., Haak H. L., Schots R., Dekker A. W., De Gast G. C., Lwenberg B., Comparison of chop chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma New England Journal of Medicine 1995 332 16 1045 1051
13. Martelli M., Vignetti M., Zinzani P. L., Gherlinzoni F., Meloni G., Fiacchini M., De Sanctis V., Papa G., Martelli M. F., Calabresi F., Tura S., Mandelli F., High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study Journal of Clinical Oncology 1996 14 2 534 542
14. Haioun C., Lepage E., Gisselbrecht C., Salles G., Coiffier B., Brice P., Bosly A., Morel P., Nouvel C., Tilly H., Lederlin P., Sebban C., Briere J., Gaulard P., Reyes F., Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocola groupe d'etude des lymphomes de l'adulte study Journal of Clinical Oncology 2000 18 16 3025 3030 (Pubitemid 30644128)
15. Kluin-Nelemans H. C., Zagonel V., Anastasopoulou A., Bron D., Roozendaal K. J., Noordijk E. M., Musson H., Teodorovic I., Maes B., Carbone A., Carde P., Thomas J., Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study Journal of the National Cancer Institute 2001 93 1 22 30 (Pubitemid 32060886)
16. Milpied N., Deconinck E., Gaillard F., Delwail V., Foussard C., Berthou C., Gressin R., Lucas V., Colombat P., Harousseau J. L., Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support New England Journal of Medicine 2004 350 13 1287 1295 (Pubitemid 38375363)
17. Gianni A. M., Bregni M., Siena S., Brambilla C., Di Nicola M., Lombardi F., Gandola L., Tarella C., Pileri A., Ravagnani F., Valagussa P., Bonadonna G., Stern A. C., Magni M., Caracciolo D., High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma New England Journal of Medicine 1997 336 18 1290 1297 (Pubitemid 27187782)
18. Santini G., Salvagno L., Leoni P., Chisesi T., De Souza C., Sertoli M. R., Rubagotti A., Congiu A. M., Centurioni R., Olivieri A., Tedeschi L., Vespignani M., Nati S., Soracco M., Porcellini A., Contu A., Guarnaccia C., Pescosta N., Majolino I., Spriano M., Vimercati R., Rossi E., Zambaldi G., Mangoni L., Endrizzi L., Sileni V. C., Miggiano M. C., Marino G., Damasio E., Rizzoli V., VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group Journal of Clinical Oncology 1998 16 8 2796 2802 (Pubitemid 28363045)
19. Gisselbrecht C., Lepage E., Molina T., Quesnel B., Fillet G., Lederlin P., Coiffier B., Tilly H., Gabarre J., Guilmin F., Hermine O., Reyes F., Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma Journal of Clinical Oncology 2002 20 10 2472 2479 (Pubitemid 34525732)
20. Kaiser U., Uebelacker I., Abel U., Birkmann J., Trmper L., Schmalenberg H., Karakas T., Metzner B., Hossfeld D. K., Bischoff H. G., Franke A., Reiser M., Mller P., Mantovani L., Grundeis M., Rothmann F., Von Seydewitz C. U., Mesters R. M., Steinhauer E. U., Krahl D., Schumacher K., Kneba M., Baudis M., Schmitz N., Pfab R., Kppler H., Parwaresch R., Pfreundschuh M., Havemann K., Randomized study to evaluate the use of high-dose therapy as part of primary treatment for aggressive lymphoma Journal of Clinical Oncology 2002 20 22 4413 4419 (Pubitemid 35334751)
21. Martelli M., Gherlinzoni F., De Renzo A., Zinzani P. L., De Vivo A., Cantonetti M., Falini B., Storti S., Meloni G., Rizzo M., Molinari A. L., Lauria F., Moretti L., Lauta V. M., Mazza P., Pescarmona L. G. E., Pileri S. A., Mandelli F., Tura S., Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial Journal of Clinical Oncology 2003 21 7 1255 1262 (Pubitemid 46606401)
22. Olivieri A., Santini G., Patti C., Chisesi T., De Souza C., Rubagotti A., Aversa S., Billio A., Porcellini A., Candela M., Centurioni R., Congiu A. M., Brunori M., Nati S., Spriano M., Vimercati R., Marino G., Contu A., Tedeschi L., Majolino I., Crugnola M., Sertoli M. R., Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG Annals of Oncology 2005 16 12 1941 1948 (Pubitemid 41724284)
23. Vitolo U., Liberati A. M., Cabras M. G., Federico M., Angelucci E., Baldini L., Boccomini C., Brugiatelli M., Calvi R., Ciccone G., Genua A., Deliliers G. L., Levis A., Parvis G., Pavone E., Salvi R., Sborgia M., Gallo E., High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an Intergruppo Italiano Linfomi randomized trial Haematologica 2005 90 6 793 801 (Pubitemid 40897221)
24. Betticher D. C., Martinelli G., Radford J. A., Kaufmann M., Dyer M. J. S., Kaiser U., Aulitzky W. E., Beck J., von Rohr A., Kovascovics T., Cogliatti S. B., Cina S., Maibach R., Cerny T., Linch D. C., Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL) Annals of Oncology 2006 17 10 1546 1552 (Pubitemid 44542042)
25. Linch D. C., Yung L., Smith P., MacLennan K., Jack A., Hancock B., Cunningham D., Hoskin P., Qian W., Holte H., Boesen A. M., Grigg A., Browett P., Trneny M., Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients 65 years with poor prognosis histologically aggressive NHL: research paper British Journal of Haematology 2010 149 2 237 243
26. Swerdlow S. H., Campo E., Harris N. L., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 4th WHO Press
27. Tarella C., Zanni M., Di Nicola M., Patti C., Calvi R., Pescarollo A., Zoli V., Fornari A., Novero D., Cabras A., Stella M., Comino A., Remotti D., Ponzoni M., Caracciolo D., Ladetto M., Magni M., Devizzi L., Rosato R., Boccadoro M., Bregni M., Corradini P., Gallamini A., Majolino I., Mirto S., Gianni A. M., Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Leukemia 2007 21 8 1802 1811 (Pubitemid 47086769)
28. Vitolo U., Chiappella A., Angelucci E., Rossi G., Liberati A. M., Cabras M. G., Botto B., Ciccone G., Gaidano G., Falchi L., Freilone R., Novero D., Orsucci L., Pavone V., Pogliani E., Rota-Scalabrini D., Salvi F., Tonso A., Tucci A., Levis A., Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study Haematologica 2009 94 9 1250 1258
29. Dilhuydy M. S., Lamy T., Foussard C., Gressin R., Casassus P., Deconninck E., Le Maignan C., Damotte D., Milpied N., Front-line high-dose chemotherapy with Rituximab showed excellent long-term survival in adults with aggressive large B-cell lymphoma: final results of a phase II GOELAMS study Biology of Blood and Marrow Transplantation 2010 16 5 672 677
30. Fitoussi O., Belhadj K., Mounier N., Survival impact of rituximab combined with ACVBP and upfront consolidative autotransplantation in high risk diffuse large B-cell lymphoma for GELA Haematologica 2011 96 1136 1143
31. Still P. J., Unger J. M., Cook J., Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP R for eight cycles to CHOP R for six cycles followed by autotransplant for patients with high-intermediate (H-int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma Journal of Clinical Oncology 2011 29, abstract a8001
32. Vitolo U., Chiappella A., Brusamolino E., A randomized multicentre phase III study for first line treatment of young patients with high-risk (aaIPI 2-3) diffuse large B-cell lymphoma (DLBCL): Rituximab plus dose-dense chemotherapy CHOP14/megaCHOP14 with or without intensified high-dose chemotheraly (HDC) and autologous stem cell transplantation (ASCT). Results of DLCL04 trial od Italian Lymphoma Foundation (FIL) Annals of Oncology 2011 22, supplement 4, a072 iv106
33. Guglielmi C., Gomez F., Philip T., Hagenbeek A., Martelli M., Sebban C., Milpied N., Bron D., Cahn J. Y., Somers R., Sonneveld P., Gisselbrecht C., Van Der Lelie H., Chauvin F., Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the parma trial Journal of Clinical Oncology 1998 16 10 3264 3269 (Pubitemid 28481620)
34. Blay J. Y., Gomez F., Sebban C., Bachelot T., Biron P., Guglielmi C., Hagenbeek A., Somers R., Chauvin F., Philip T., The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial Blood 1998 92 10 3562 3568 (Pubitemid 28525180)
35. Hamlin P. A., Zelenetz A. D., Kewalramani T., Qin J., Satagopan J. M., Verbel D., Noy A., Portlock C. S., Straus D. J., Yahalom J., Nimer S. D., Moskowitz C. H., Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma Blood 2003 102 6 1989 1996 (Pubitemid 37122371)
36. Kewalramani T., Zelenetz A. D., Nimer S. D., Portlock C., Straus D., Noy A., O'Connor O., Filippa D. A., Teruya-Feldstein J., Gencarelli A., Qin J., Waxman A., Yahalom J., Moskowitz C. H., Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood 2004 103 10 3684 3688 (Pubitemid 38596282)
37. Sieniawski M., Staak O., Glossmann J. P., Reineke T., Scheu H., Diehl V., Engert A., Josting A., Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma Annals of Hematology 2007 86 2 107 115 (Pubitemid 44964002)
38. Vellenga E., Van Putten W. L. J., Van 't Veer M. B., Zijlstra J. M., Fibbe W. E., Van Oers M. H. J., Verdonck L. F., Wijermans P. W., Van Imhoff G. W., Lugtenburg P. J., Huijgens P. C., Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial Blood 2008 111 2 537 543
39. Mounier N., Canals C., Gisselbrecht C., High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow transplantation registry. Biology of Blood and Marrow Transplantation. In press
40. Martn A., Conde E., Arnan M., R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study Haematologica 2008 93 12 1829 1836
41. Fenske T. S., Hari P. N., Carreras J., Zhang M. J., Kamble R. T., Bolwell B. J., Cairo M. S., Champlin R. E., Chen Y. B., Freytes C. O., Gale R. P., Hale G. A., Ilhan O., Khoury H. J., Lister J., Maharaj D., Marks D. I., Munker R., Pecora A. L., Rowlings P. A., Shea T. C., Stiff P., Wiernik P. H., Winter J. N., Rizzo J. D., van Besien K., Lazarus H. M., Vose J. M., Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma Biology of Blood and Marrow Transplantation 2009 15 11 1455 1464
42. Gisselbrecht C., Glass B., Mounier N., Singh Gill D., Linch D. C., Trneny M., Bosly A., Ketterer N., Shpilberg O., Hagberg H., Ma D., Brire J., Moskowitz C. H., Schmitz N., Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era Journal of Clinical Oncology 2010 28 27 4184 4190
43. Khouri I. F., Saliba R. M., Hosing C., Okoroji G. J., Acholonu S., Anderlini P., Couriel D., De Lima M., Donato M. L., Fayad L., Giralt S., Jones R., Korbling M., Maadani F., Manning J. T., Pro B., Shpall E., Younes A., McLaughlin P., Champlin R. E., Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas Journal of Clinical Oncology 2005 23 10 2240 2247 (Pubitemid 46218716)
44. Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Badger C. C., Nelp W. B., Glenn S., Butchko G., Fisher D., Porter B., Matthews D. C., Fisher L. D., Bernstein I. D., Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support New England Journal of Medicine 1993 329 17 1219 1224 (Pubitemid 23306322)
45. Krishnan A., Nademanee A., Fung H. C., Raubitschek A. A., Molina A., Yamauchi D., Rodriguez R., Spielberger R. T., Falk P., Palmer J. M., Forman S. J., Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma Journal of Clinical Oncology 2008 26 1 90 95
46. Winter J. N., Inwards D. J., Spies S., Wiseman G., Patton D., Erwin W., Rademaker A. W., Weitner B. B., Williams S. F., Tallman M. S., Micallef I., Mehta J., Singhal S., Evens A. M., Zimmer M., Molina A., White C. A., Gordon L. I., Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-hodgkin's lymphoma Journal of Clinical Oncology 2009 27 10 1653 1659
47. Alizadeh A. A., Eisen M. B., Davis R. E., Ma C. L., Lossos I. S., Rosenwald A., Boldrick J. C., Sabet H., Tran T., Yu X., Powell J. I., Yang L., Mar G. E., Moore T., Hudson J., Lu L., Lewis D. B., Tibshirani R., Sherlock G., Chan W. C., Greiner T. C., Weisenburger D. D., Armitage J. O., Warnke R., Levy R., Wilson W., Grever M. R., Byrd J. C., Botstein D., Brown P. O., Staudt L. M., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 2000 403 6769 503 511 (Pubitemid 30082188)
48. Rosenwald A., Wright G., Chan W. C., Connors J. M., Campo E., Fisher R. I., Gascoyne R. D., Konrad Muller-Hermelink H., Smeland E. B., Giltnane J. M., Hurt E. M., Zhao H., Averett L., Yang L., Wilson W. H., Jaffe E. S., Simon R., Klausner R. D., Powell J., Duffey P. L., Longo D. L., Greiner T. C., Weisenburger D. D., Sanger W. G., Dave B. J., Lynch J. C., Vose J., Armitage J. O., Montserrat E., Lpez-Guillermo A., Grogan T. M., Miller T. P., Leblanc M., Ott G., Kvaloy S., Delabie J., Holte H., Krajci P., Stokke T., Staudt L. M., The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma New England Journal of Medicine 2002 346 25 1937 1947 (Pubitemid 34651353)
49. Wright G., Tan B., Rosenwald A., Hurt E. H., Wiestner A., Staudt L. M., A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma Proceedings of the National Academy of Sciences of the United States of America 2003 100 17 9991 9996 (Pubitemid 37087056)
50. Van Imhoff G. W., Boerma E. J. G., Van Der Holt B., Schuuring E., Verdonck L. F., Kluin-Nelemans H. C., Kluin P. M., Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma Journal of Clinical Oncology 2006 24 25 4135 4142 (Pubitemid 46622290)
51. Lenz G., Wright G., Dave S. S., Xiao W., Powell J., Zhao H., Xu W., Tan B., Goldschmidt N., Iqbal J., Vose J., Bast M., Fu K., Weisenburger D. D., Greiner T. C., Armitage J. O., Kyle A., May L., Gascoyne R. D., Connors J. M., Troen G., Holte H., Kvaloy S., Dierickx D., Verhoef G., Delabie J., Smeland E. B., Jares P., Martinez A., Lopez-Guillermo A., Montserrat E., Campo E., Braziel R. M., Miller T. P., Rimsza L. M., Cook J. R., Pohlman B., Sweetenham J., Tubbs R. R., Fisher R. I., Hartmann E., Rosenwald A., Ott G., Muller-Hermelink H. K., Wrench D., Lister T. A., Jaffe E. S., Wilson W. H., Chan W. C., Staudt L. M., Stromal gene signatures in large-B-cell lymphomas New England Journal of Medicine 2008 359 22 2313 2323
52. Hans C. P., Weisenburger D. D., Greiner T. C., Gascoyne R. D., Delabie J., Ott G., Mller H. K., Campo E., Braziel R. M., Jaffe E. S., Pan Z., Farinha P., Smith L. M., Falini B., Banham A. H., Rosenwald A., Staudt L. M., Connors J. M., Armitage J. O., Chan W. C., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 2004 103 1 275 282 (Pubitemid 38029949)
53. Choi W. W. L., Weisenburger D. D., Greiner T. C., Piris M. A., Banham A. H., Delabie J., Braziel R. M., Geng H., Iqbal J., Lenz G., Vose J. M., Hans C. P., Fu K., Smith L. M., Li M., Liu Z., Gascoyne R. D., Rosenwald A., Ott G., Rimsza L. M., Campo E., Jaffe E. S., Jaye D. L., Staudt L. M., Chan W. C., A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy Clinical Cancer Research 2009 15 17 5494 5502
54. Nyman H., Jerkeman M., Karjalainen-Lindsberg M. L., Banham A. H., Lepp S., Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP Modern Pathology 2009 22 8 1094 1101
55. Ott G., Ziepert M., Klapper W., Horn H., Szczepanowski M., Bernd H. W., Thorns C., Feller A. C., Lenze D., Hummel M., Stein H., Mller-Hermelink H. K., Frank M., Hansmann M. L., Barth T. F. E., Mller P., Cogliatti S., Pfreundschuh M., Schmitz N., Trmper L., Loeffler M., Rosenwald A., Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL Blood 2010 116 23 4916 4925
56. Jais J. P., Haioun C., Molina T. J., Rickman D. S., de Reynies A., Berger F., Gisselbrecht C., Brire J., Reyes F., Gaulard P., Feugier P., Labouyrie E., Tilly H., Bastard C., Coiffier B., Salles G., Leroy K., The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab Leukemia 2008 22 10 1917 1924
57. Thieblemont C., Briere J., Mounier N., Voelker H.-U., Cuccuini W., Hirchaud E., Rosenwald A., Jack A., Sundstrom C., Cogliatti S., Trougouboff P., Boudova L., Ysebaert L., Soulier J., Chevalier C., Bron D., Schmitz N., Gaulard P., Houlgatte R., Gisselbrecht C., The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study Journal of Clinical Oncology 2011 29 31 4079 4087
58. Gu K., Weisenburger D. D., Fu K., Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation. Hematological Oncology. In press